BioMarin Pharmaceutical Inc. (BMRN): Price and Financial Metrics


BioMarin Pharmaceutical Inc. (BMRN): $86.85

2.30 (+2.72%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add BMRN to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

BMRN POWR Grades


  • BMRN scores best on the Value dimension, with a Value rank ahead of 82.53% of US stocks.
  • BMRN's strongest trending metric is Value; it's been moving down over the last 179 days.
  • BMRN ranks lowest in Momentum; there it ranks in the 12th percentile.

BMRN Stock Summary

  • Biomarin Pharmaceutical Inc's market capitalization of $14,641,598,809 is ahead of 84.74% of US-listed equities.
  • The price/operating cash flow metric for Biomarin Pharmaceutical Inc is higher than 89.14% of stocks in our set with a positive cash flow.
  • In terms of twelve month growth in earnings before interest and taxes, Biomarin Pharmaceutical Inc is reporting a growth rate of 361.18%; that's higher than 93.93% of US stocks.
  • If you're looking for stocks that are quantitatively similar to Biomarin Pharmaceutical Inc, a group of peers worth examining would be GTHX, AAOI, IVAC, FORM, and INSG.
  • Visit BMRN's SEC page to see the company's official filings. To visit the company's web site, go to www.biomarin.com.

BMRN Valuation Summary

  • BMRN's price/sales ratio is 8.1; this is 113.16% higher than that of the median Healthcare stock.
  • Over the past 243 months, BMRN's price/sales ratio has gone down 31.8.
  • BMRN's price/sales ratio has moved down 31.8 over the prior 243 months.

Below are key valuation metrics over time for BMRN.

Stock Date P/S P/B P/E EV/EBIT
BMRN 2021-08-31 8.1 3.6 18.4 -377.5
BMRN 2021-08-30 8.0 3.6 18.2 -373.4
BMRN 2021-08-27 8.0 3.6 18.3 -374.5
BMRN 2021-08-26 7.5 3.4 17.3 -354.0
BMRN 2021-08-25 7.5 3.4 17.2 -352.7
BMRN 2021-08-24 7.4 3.3 16.9 -347.2

BMRN Growth Metrics

    Its 3 year cash and equivalents growth rate is now at 34.73%.
  • Its 2 year net cashflow from operations growth rate is now at 201.39%.
  • Its 3 year price growth rate is now at -1.35%.
Over the past 34 months, BMRN's revenue has gone up $327,765,000.

The table below shows BMRN's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-12-31 1,846.275 304.536 -64.08
2021-09-30 1,848.582 279.972 15.917
2021-06-30 1,916.624 269.118 837.214
2021-03-31 1,844.416 214.071 795.09
2020-12-31 1,860.455 85.365 859.1
2020-09-30 1,862.781 156.092 852.025

BMRN's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • BMRN has a Quality Grade of C, ranking ahead of 36.95% of graded US stocks.
  • BMRN's asset turnover comes in at 0.314 -- ranking 144th of 682 Pharmaceutical Products stocks.
  • APVO, IRWD, and AVEO are the stocks whose asset turnover ratios are most correlated with BMRN.

The table below shows BMRN's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-09-30 0.314 0.742 -0.006
2021-06-30 0.323 0.707 -0.008
2021-03-31 0.319 0.711 -0.019
2020-12-31 0.338 0.718 -0.003
2020-09-30 0.357 0.735 0.005
2020-06-30 0.383 0.782 0.022

BMRN Price Target

For more insight on analysts targets of BMRN, see our BMRN price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $110.83 Average Broker Recommendation 1.4 (Moderate Buy)

BMRN Stock Price Chart Interactive Chart >

Price chart for BMRN

BMRN Price/Volume Stats

Current price $86.85 52-week high $94.20
Prev. close $84.55 52-week low $70.73
Day low $81.75 Volume 2,260,200
Day high $86.98 Avg. volume 1,293,748
50-day MA $78.94 Dividend yield N/A
200-day MA $81.58 Market Cap 16.07B

BioMarin Pharmaceutical Inc. (BMRN) Company Bio


BioMarin Pharmaceutical develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions. The company was founded in 1996 and is based in San Rafael, California.


BMRN Latest News Stream


Event/Time News Detail
Loading, please wait...

BMRN Latest Social Stream


Loading social stream, please wait...

View Full BMRN Social Stream

Latest BMRN News From Around the Web

Below are the latest news stories about Biomarin Pharmaceutical Inc that investors may wish to consider to help them evaluate BMRN as an investment opportunity.

BioMarin Clocks Flat Q4 Sales Despite Erosion oF US Kuvan Market

BioMarin Pharmaceutical Inc (NASDAQ: BMRN ) reported a 1% Y/Y decrease in Q4 revenue to $449.8 million , beating the consensus estimate of $442.39 million. The decline was attributable to lower sales from Kuvan and Naglazyme, cushioned by higher revenues from Aldurazyme, Vimizim, and Palynziq. Kuvan sales decreased 23% to $ 68.5 million, primarily due to generic competition. Lower Naglazyme product revenues declined 31% to $83.1 million, primarily driven by … Full story available on Benzinga.com

Benzinga | February 24, 2022

Why BioMarin Pharmaceutical Tumbled on Thursday

While the company broadly met expectations for the fourth quarter, investors seemed concerned about its 2022 guidance.

Yahoo | February 24, 2022

BioMarin (BMRN) Q4 Earnings Top Estimates, Sales Fall Y/Y

Biomarin Pharmaceutical's (BMRN) fourth-quarter earnings and sales beat estimates. Stock declines

Yahoo | February 24, 2022

BioMarin Pharmaceutical GAAP EPS of -$0.32 beats by $0.02, revenue of $449.8M beats by $7.42M

BioMarin Pharmaceutical press release (BMRN): Q4 GAAP EPS of -$0.32 beats by $0.02.Revenue of $449.8M (-0.5% Y/Y) beats by $7.42M.For FY2022, the company expects revenue between…

Seeking Alpha | February 23, 2022

BioMarin Pharmaceutical Inc. (BMRN) CEO J.J. Bienaime on Q4 2021 Results - Earnings Call Transcript

No summary available.

Seeking Alpha | February 23, 2022

Read More 'BMRN' Stories Here

BMRN Price Returns

1-mo 7.26%
3-mo 10.83%
6-mo -2.88%
1-year 2.43%
3-year 3.36%
5-year -3.10%
YTD -1.70%
2021 0.75%
2020 3.71%
2019 -0.70%
2018 -4.51%
2017 7.64%

Continue Researching BMRN

Here are a few links from around the web to help you further your research on Biomarin Pharmaceutical Inc's stock as an investment opportunity:

Biomarin Pharmaceutical Inc (BMRN) Stock Price | Nasdaq
Biomarin Pharmaceutical Inc (BMRN) Stock Quote, History and News - Yahoo Finance
Biomarin Pharmaceutical Inc (BMRN) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.5296 seconds.